Detalhe da pesquisa
1.
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1ß dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.
Ann Rheum Dis;
78(3): 413-420, 2019 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30552176
2.
Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab.
J Immunother;
45(3): 167-179, 2022 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35034046
3.
A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
Cancer Immunol Res;
7(11): 1864-1875, 2019 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31462409
4.
Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells.
J Immunol Res;
2017: 5737159, 2017.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29075649
5.
Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.
J Exp Ther Oncol;
5(4): 273-86, 2006.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17024968